Get all your news in one place.
100’s of premium titles.
One app.
Start reading
Benzinga
Benzinga
Technology
Vandana Singh

MorphoSys Discontinues US Discovery Activities, Takes €231M Impairment Charge

  • MorphoSys AG (NASDAQ:MOR) has reported a non-cash impairment charge of €231 million on goodwill after consolidating research and discovery functions.
  • This write-down results from the consolidation of the Company's research and discovery activities after the acquisition of Constellation Pharmaceuticals.
  • MorphoSys decided to focus its research activities on the most advanced programs and centralize all laboratory activities at its German research hub in Planegg, Germany.
  • Read Next: MorphoSys Presents Early Felzartamab Data From Autoimmune Kidney Disease Trial.
  • All US-based activities relating to discovery biology and drug discovery departments were discontinued.
  • Early pipeline projects cannot be realized anymore, and the expected cash flows from these projects will not materialize accordingly.
  • Price Action: MOR shares are down 0.93% at $6.42 during the market session on the last check Thursday.
Sign up to read this article
Read news from 100’s of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.